Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a Stage I trial

American Journal on Addictions

Volumn 15, Issue 2, 2006, Pages 150-159

  Sullivan, Maria A ^a,b,f   Rothenberg, Jami L ^a,b   Vosburg, Suzanne K ^a,b   Church, Sarah H ^c   Feldman, Shara J ^d   Epstein, Eva M ^e   Kleber, Herbert D ^a,b   Nunes, Edward V ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d ST JOHN'S UNIVERSITY   (United States)

^e TEMPLE UNIVERSITY   (United States)

^f Department of Psychiatry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; METHADONE; NALTREXONE; OPIATE;

ADULT; AGE DISTRIBUTION; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DEPRESSION; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; FEMALE; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MALE; METHADONE TREATMENT; MULTIPLE REGRESSION; OPIATE ADDICTION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PREDICTION; RISK; STATISTICAL MODEL; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT DROPOUTS; SUBSTANCE ABUSE, INTRAVENOUS; TOKEN ECONOMY;

EID: 33645778333     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490500528464     Document Type: Article

References (59)

1. Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Liberman RP. The treatment of heroin addiction: naltrexone alone and with behavior therapy. The International of the Addictions. 1980;15:795-807.
2. Kosten T, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984;10:249-266.
3. De Leon G, Schwartz S. Therapeutic communities: what are the retention rates? Am J Drug Alcohol Abuse. 1984;10:267-284.
4. Guydish J, Werdegar D, Sorensen JL, Clark W, Acampora A. A day treatment program in a therapeutic community setting: six-month outcomes. The Walden House Day Treatment Program. J Subst Abuse Treat. 1995;12:441-447.
5. Keen J, Oliver P, Rowse G, Mathers N. Residential rehabilitation for drug users: a review of thirteen months' intake to a therapeutic community. Fam Pract. 2001;18:545-548.
6. Greenstein RA, Evans BD, McLellan AT, O'Brien CP. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend. 1983;12:173-180.
7. Greenstein RA, Resnick RB, Resnick E. Methadone and naltrexone in the treatment of heroin dependence: Symposium on Clinical Psychopharmacology II. Psychiatr Clin North Am. 1984;7:671-679.
8. Washton AM, Gold MS, Pottash AC. Successful use of naltrexone in addicted physicians and business executives. Advanced Alcohol and Substance Abuse. 1984;4:89-96.
9. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest. 2003;33:824-829.
10. Kirchmayer U, Davoli M, Verster A, Amato L, Feri M, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction. 2002;97:1241-1249.
11. Grabowski J, O'Brien C, Greenstein R, Ternes J. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse. 1979;6:355-365.
12. Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54:125-137.
13. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58:755-761.
14. Silverman K, Wong CJ, Higgins ST, et al. Increasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend. 1996;41:157-165.
15. Higgins ST, Alessi SM, Dantona RL. Voucher-based incentives: a substance abuse treatment innovation. Addict Behav. 2002;27:887-910.
16. Rothenberg JL, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: an integrated therapy for opiate dependence. J Subst Abuse Treat. 2002;23:351-360.
17. Collins ED, Whittington RA, Heitler NE, Kleber HD. A randomized comparison of anesthesia-assisted heroin detoxification with buprenorphine- and clonidine-assisted detoxifications. Presentation at College on Problems of Drug Dependence 63rd Annual Scientific Meeting, Scottsdale, Arizona, June 16-21, 2001.
18. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med. 1997;127: 526-530.
19. Kosten T, Morgan C, Kleber HD. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Res Monogr. 1992;121:101-119.
20. Stine SM, Kosten TR. Use of drug combinations in treatment of opioid withdrawal. J Clin Psychopharmacol. 1992;12:203-209.
21. Hunt GM, Azrin NH. A community reinforcement approach to alcoholism. Behav Res Ther. 1973;11:91-104.
22. Galanter M. Network therapy for addiction: a model for office practice. Am J Psychiatry. 1993;150(1):28-36.
23. Galanter M, Keller DS, Dermatis H. Network therapy for addiction: assessment of the clinical outcome of training. Am J Drug Alcohol Abuse. 1997;23:355-367.
24. Meyers R, Smith J. The community reinforcement approach. In: Reid HK, Miller W, eds. Handbook of Alcoholism Treatment Approaches Effective Alternatives. 2nd ed. Boston, MA: Allyn and Bacon; 1995.
25. O'Connor PG, Waugh ME, Schottenfeld RS, Diakongiannis IA, Rounsaville BJ. Ambulatory opiate detoxification and primary care: a role for the primary care physician. J Gen Intern Med. 1992;7:532-534.
26. Dubbert PM, King A, Rapp S, Brief D, Martin JE, Lake M. Riboflavin as a tracer of medication compliance. J Behav Med. 1985;8:287-299.
27. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20:1412-1417.
28. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
29. Sobell MB, Maisto SA, Sobell LC, Cooper AM, Cooper T, Sanders B. Developing a prototype for evaluating treatment effectiveness. In: Sobell LC, Sobell MD, Ward E, eds. Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. New York: Pergamon Press, 1980;129-150.
30. Montogomery HA, Miller WR, Tonigan JS, Hester RK, Abbot PJ, Delaney HD. SOCRATES as presage: validation of a new instrument for assessing motivation for behavior change in problem drinkers. Paper presented at annual meeting of the Association for Advancement of Behavior Therapy, San Francisco, Colif., November, 1990.
31. Charney DS, Heninger G, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry. 1986;143:831-837.
32. Resnick RB, Washton AM. Clinical outcome with naltrexone: predictor variables and follow-up status in detoxified heroin addicts. Ann N Y Acad Sci. 1978;311:241-246.
33. Carroll KM, Power M-ED, Bryant K, Rounsaville BJ. One-year follow-up status of treatment-seeking cocaine abusers: psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 1993;181:71-79.
34. Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93:73-92.
35. Kutz I, Reznik V. Rapid heroin detoxification using a single high dose of buprenorphine. J Psychoactive Drugs. 2001;33:191-193.
36. Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend. 1999;56:181-190.
37. Aceto MD. Characterization of prototypical opioid antagonists, agonist-antagonists, and agonists in the morphine-dependent rhesus monkey. Neuropeptides. 1984;5:1-3, 15-18.
38. Stitzer ML, Iguchi MY, Kidorf M, Bigelow GE. Contingency management in methadone treatment: the case for positive incentives. NIDA Res Monogr. 1993;137:19-36.
39. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991;148(9): 1218-1224.
40. Higgins ST, Petry NM. Contingency management: incentives for sobriety. Alcohol Res Health. 1999;23:122-127.
41. Budney AJ, Higgins SY, Delaney DD, Kent L, Bickel WK. Contingent reinforcement of abstinence with individuals abusing cocaine and marijuana. J Appl Behav Anal. 1991;24:657-665.
42. Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber HD. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39:151-156.
43. Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD. Prognostic significance of psychopathology in treated opiate addicts: a 2.5-year follow-up study. Arch Gen Psychiatry. 1986;43:739-745.
44. Kokkevi A, Stefanis N, Anastasopoulou E, Kostogianni C. Personality disorders in drug abusers: prevalence and their association with Axis I disorders as predictors of treatment retention. Addict Behav. 1998;23:841-853.
45. Nunes EV, Quitkin FM, Donovan S, et al. Imipramine treatment of opiate dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153-160.
46. Hamilton S, Nunes E, Klimchak C. Treatment of depressed methadone maintenance patients with nefazodone: a case series. Am J Addict. 1998;7:309-312.
47. Nunes EV, Quitkin FM, Brady R, Koenig T. Antidepressant treatment in methadone maintenance patients. J Addict Dis. 1994;13: 13-24.
48. Woody GE, O'Brien BP, Rickels K. Depression and anxiety in heroin addicts: a placebo controlled study of doxepin in combination with methadone. Am J Psychiatry. 1975;132:447-450.
49. Gerra G, Fertonani G, Zaimovic A, et al. Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment. Prog Neuro-Psychopharamacol Biol Psychiatry. 1995;19:1225-1237.
50. Landabaso MA, Iraurgi I, Jimenez-Lerma JM, et al. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction. 1998;93:739-744.
51. Hitsman B, Mahableshwarkar A, Pingitore R, et al. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol. 1999;67:547-554.
52. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55:683-690.
53. Hurt RD, Sachs DPL, Gloner ED, et al. A comparison of sustained-release bupropion, and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
54. Volpicelli JR, Alterman AI, Hayashida A, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
55. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Mayer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49: 881-887.
56. Mason BJ, Ritvo ED, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162-1167.
57. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719-724.
58. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr. 1995;150:37-52.
59. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse, and survival among opiate addicts after treatment: a prospective follow-up study. Br J Psychiatry. 1989;154:348-353.